Association Between Plaque Thickness of the Thoracic Aorta and Recurrence of Atrial Fibrillation After Ablation by Hwang, Hui-Jeong et al.
177
Print ISSN 1738-5520 / On-line ISSN 1738-5555
Copyright © 2011 The Korean Society of Cardiology
ORIGINAL ARTICLE
DOI 10.4070/kcj.2011.41.4.177
Open Access
Association Between Plaque Thickness of the Thoracic Aorta and
Recurrence of Atrial Fibrillation After Ablation
Hui-Jeong Hwang, MD, Man-Young Lee, MD, Ho-Joong Youn, MD, Yong-Seog Oh, MD, Tae-Ho Rho, MD, 
Wook-Sung Chung, MD, Chul-Soo Park, MD, Yun-Seok Choi, MD, Woo-Baek Chung, MD,  
Jae-Beom Lee, MD, Hyun-Keun Park, MD, KeunJoon Lim, MD, and Jae Hak Lee, MD
Department of Internal Medicine, College of Medicine, The Catholic University of Korea, Seoul, Korea
ABSTRACT
Background and Objectives: Several predictors of recurrence of atrial fibrillation (AF) after ablation have been identified, 
including age, type of AF, hypertension, left atrial diameter and impaired left ventricular ejection fraction. The aim of this 
study was to investigate whether the atherosclerotic plaque thickness of the thoracic aorta is associated with a recurrence of 
AF after circumferential pulmonary vein ablation (CPVA). Subjects and Methods: Among patients with drug-refractory 
paroxysmal or persistent AF, 105 consecutive (mean age 58±11 years, male : female=76 : 29) patients who underwent trans-
esophageal echocardiography and CPVA were studied. The relationships between the recurrence of AF and variables, includ-
ing clinical characteristics, plaque thickness of the thoracic aorta, laboratory findings and echocardiographic parameters were 
evaluated. Results: A univariate analysis showed that the presence of diabetes {hazard ratio (HR)=3.425; 95% confidence 
interval (CI), 1.422-8.249, p=0.006}, ischemic heart disease (HR=4.549; 95% CI, 1.679-12.322, p=0.003), duration of AF 
(HR=1.010; 95% CI, 1.001-1.018, p=0.025), type of AF (HR=2.412, 95% CI=1.042-5.584, p=0.040) and aortic plaque thick-
ness with ≥4 mm (HR=9.514; 95% CI, 3.419-26.105, p<0.001) were significantly associated with the recurrence of AF after 
ablation. In Cox multivariate regression analysis, only the aortic plaque thickness (with ≥4 mm) was an independent predic-
tor of recurrence of AF after ablation (HR=7.250, 95% CI=1.906-27.580, p=0.004). Conclusion: Significantly increased 
aortic plaque thickness can be a predictable marker of recurrence of AF after CPVA. (Korean Circ J 2011;41:177-183)
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Introduction
Atrial fibrillation (AF) is an important risk factor for stroke, 
thromboembolism and congestive heart failure, leading to sub-
stantial morbidity and mortality from cardiovascular and ce-
rebrovascular events.
1-3) The development of AF is influenced 
by age,
4)5) gender,
4)6) ischemic heart disease (IHD),
7) valvular 
heart disease and cardiovascular risk factors, such as hyper-
tension,
8) diabetes
7) and obesity.
9) Some reports have also sug-
gested that atherosclerosis is associated with the occurrence 
of AF.
10-13) 
Catheter ablation has emerged as a therapeutic option in 
patients with symptomatic, drug-resistant AF. However, the 
recurrence rate of AF after an ablation procedure has been re-
ported to be variable, ranging from 15-30%.
8)14)15) Prior studies 
have identified a number of predictors of outcome following 
AF ablation, including age,
5) type of AF,
5) hypertension,
8) left 
atrial (LA) diameter
5)8) and impaired left ventricular ejection 
fraction (LVEF).
8)16) The aim of this study was to investigate 
whether aortic plaque thickness measured by transesopha-
geal echocardiography (TEE), is associated with the recur-
rence of AF after circumferential pulmonary vein ablation 
(CPVA). 178   Aortic Plaque and Atrial Fibrillation 
Subjects and Methods
Patient population
We retrospectively evaluated 105 consecutive patients (mean 
age 58±11 years, male : female=76 : 29) who underwent cir-
cumferential pulmonary vein (PV) mapping and ablation be-
cause of symptomatic, drug-refractory paroxysmal AF (PAF) 
or persistent AF (PeAF), between June 2005 and January 2009. 
All the patients had been refractory to the treatment with at 
least one antiarrhythmic agent, including class I or class III 
drugs. Transthoracic echocardiography (TTE) and TEE were 
performed before the ablation procedure. Clinical data were 
collected from the patients’ through telephone interviews, and 
from the medical records during follow-up. 
The duration of AF was determined based on the clinical 
symptoms and or electrocardiographic documentation. PAF 
was defined as the occurrence of two or more episodes of AF 
during the previous 12 months, typically lasting <7 days and 
terminating spontaneously. PeAF was defined as the occurr-
ence of episodes of AF sustained beyond 7 days, and usually 
requiring pharmacological therapy or cardioversion for the 
restoration of a normal sinus rhythm.
17) The recurrence of AF 
was defined as a documented episode of AF lasting for >30 se-
conds on electrocardiography (ECG) or 24-hour Holter moni-
toring.
18) AF episodes within the first three months after the 
ablation procedure were not considered in the evaluation of 
the final success rates because they are often described as trans-
ient recurrences related to the atrial inflammatory processes 
following ablative lesions.
18)19)
The patients were informed of the investigative nature of 
the study and their written consent was obtained prior to their 
participation in the study. This study was approved by the In-
stitutional Review Board of St. Mary’s Hospital, The Catholic 
University of Korea (SC10RISI0031). 
Transesophageal echocardiographic assessment 
of the thoracic aorta
TEE was performed according to standard practice guide-
lines
20) using commercially available ultrasonographic instru-
ments (GE Healthcare Vivid 7 Pro equipped with 5 MHz tr-
ansesophageal probe and Hewlett-Packard SONOS 5500 equ-
ipped with 6 MHz probe). Peak velocity (Vmax) of the left 
atrial appendage (LAA) flow was recorded within 1 cm of the 
orifice of the appendage with pulse-wave Doppler interroga-
tion, and evaluated in antegrade (emptying) directions, aver-
aged over three consecutive cardiac cycles. Plaque was defin-
ed as an irregular intimal thickening of ≥1 mm protruding 
into the lumen with echogenicity. The plaque thickness was 
defined as the distance between the medial-adventitial bor-
der of the thoracic aorta and the internal side of the plaque. 
For examining the aortic plaque thickness, the transducer was 
pulled back from the level of the aortic valve (35-40 mm from 
the incisor) to the level of the aortic arch (15-20 mm from 
the incisor). The largest plaque measured in any region of the 
thoracic aorta was selected and plaques were classified into 
three categories based on the definition of simple vs. complex 
plaque depending on the plaque size:
20)21) <1 mm, 1-4 mm 
and >4 mm thickness (Fig. 1). 
Transthoracic echocardiographic assessment 
Prior to the ablation procedure, all the patients underwent 
TTE for assessment of cardiac structure and function. TTE 
was performed using the aforementioned echocardiographic 
instruments equipped with 4- to 5-MHz transthoracic trans-
ducers. 
Left ventricular end diastolic diameter, left ventricular end 
systolic diameter and anteroposterior left atrial diameter 
(LAD) were measured by M-mode echocardiography in the pa-
rasternal view. LVEF was calculated using Simpson’s method.
22) 
Catheter ablation procedure 
The patients were given oral anticoagulation for at least one 
month; this was stopped three days before the ablation proce-
dure, intravenous heparin was infused from the day of admis-
sion to one day before the ablation procedure. Antiarrhyth-
mic agents were stopped at least five half-lives before the ab-
lation procedure, but amiodarone was stopped at least three 
weeks before the procedure. A PV CT was performed before 
the ablation procedure to integrate the anatomy of the left at-
rium (LA) and PV into a three dimensional (D) mapping sys-
tem (CARTO, Biosense-Webster, Diamond Bar, CA, USA). 
Catheters were introduced through the left femoral vein and 
A   B C  
Fig. 1. Short-axis transesophageal echocardiographic views of the thoracic aorta showing aortic plaque thickness. A: plaques with ˂1 mm 
thickness. B: 2.2 mm plaque thickness (1-3.9 mm). C: 7 mm plaque thickness (≥4 mm).Hui-Jeong Hwang, et al.   179
right jugular vein. A 7 French (Fr) decapolar electrode cath-
eter was positioned in the coronary sinus, a 6 Fr quadripolar 
catheter was placed in the right atrium and a hexapolar ca-
theter was positioned in the His bundle recording area. A pig-
tail catheter was introduced into the main pulmonary artery 
through the right femoral vein. Pulmonary venograms were 
then obtained during the venous phase of the ipsilateral pul-
monary angiography. After obtaining a transseptal access to 
the LA, an intravenous bolus of heparin (5,000 IU) was ad-
ministered, and an additional bolus injection was delivered 
to maintain an activated clotting time between 250-350 sec-
onds during the procedure. Mapping was performed during 
sinus rhythm. An irrigation tip catheter (7 Fr NaviStar ther-
mocool, Biosense Webster Diamond Bar, CA, USA) was used 
for electroanatomical 3D mapping and ablation. A Lasso ca-
theter was placed in each ipsilateral PV antrum (Fig. 2A). CP-
VA was performed along the ipsilateral PV antrum using a 
Lasso catheter as an electrical reference for electrical PV isolat-
ion using the CartoMerge mapping system, and roof line abl-
ation was then added (Fig. 2B). Supplementary linear lesions 
were deployed along the mitral isthmus, if the induced AF per-
sisted or was repeatedly induced. A target temperature for the 
ablation was 42°C at a maximal power output of 35 W. The 
end point of the ablation was defined by the disappearance of 
PV potentials and non-inducibility of sustained AF during 
isoproterenol infusion and coronary sinus pacing.
 
Follow-up
The patients were followed up in the outpatient clinic at 
1-2 weeks after the ablation procedure and every 1-3 months 
thereafter. A routine 24-hour Holter monitoring was perform-
ed before each visit, and a 12-lead ECG was obtained at each 
visit. The patients were asked to report to the emergency room 
for an ECG if any symptoms suggestive of a recurrence occurr-
ed between the scheduled visits.
After the ablation, all patients received anti-arrhythmic treat-
ment for at least one month to protect against early recurr-
ences and continued oral anticoagulation for a minimum of 
two months to maintain an international normalized ratio be-
tween 2.0 and 3.0. A minimum follow-up of three months was 
required.
Statistical analyses
The Statistical Package for the Social Sciences (SPSS) for 
Windows, version 12.0 was used for all analyses. The contin-
uous variables are presented as the mean values±standard 
deviations. For continuous variables, the groups were com-
pared using a Student’s t-test, and for categorical variables, 
the differences between the groups were analyzed using the 
chi-squared test or Fisher’s exact test. A Cox multivariate re-
gression analysis was performed to determine the predictors 
of the recurrence of AF after CPVA. Statistical significance 
was considered at p of less than 0.05.
Results
Baseline clinical characteristics 
Baseline clinical characteristics of the patients are shown 
Fig. 2. Catheter ablation procedure for AF. A: a large sized Lasso catheter placed at the left and right ipsilateral circumferential pulmonary vein 
antrum. B: electroanatomic mapping and ablation (red dots) of the left and right antrum, roof line and mitral isthmus of the left atrium. Abl.: ab-
lation catheter, HRA: high right atrium, CS: coronary sinus, His: His bundle, Lt.: left, Rt.: right, PV: pulmonary vein.
35 mm Lasso at Lt. PV antrum
Lt. Antral Ablation Rt. Antral Ablation Roof Line (↑) Ablation Mitral isthmus (▲) Ablation
35 mm Lasso at Rt. PV antrum180   Aortic Plaque and Atrial Fibrillation 
in Table 1. The mean age of the 105 patients was 58±11 years 
of whom 72% were men. Diabetes, hypertension, stroke, 
IHD and valvular heart disease were present in 11.4%, 39%, 
4.8%, 6.7% and 16.2%, respectively. Only one patient had an 
impaired systolic function with a LVEF <45%. The type of AF 
was PAF in 56 patients (53%) and PeAF in 49 patients (47%). 
Atrial fibrillation recurrence and predictive variables
Linear lesions along the mitral isthmus were deployed in 
37 patients (35% of all patients); 31 patients were free of symp-
toms of recurrence of AF and 6 patients had recurrence of AF, 
but there was no significant difference between both the gr-
oups (p=0.135) (Table 1). After the ablation procedure, the 
mean follow-up duration was 23 months (range 6-40). The re-
currence of AF developed in 26 patients (25%); of this 57.6% 
of patients had PeAF. Patients with recurrence of AF had a 
significantly higher prevalence of diabetes (26.9% vs. 6.3%, 
p=0.009), IHD (20.8% vs. 2.6%, p=0.008) and a thicker aor-
tic plaque (>4 mm plaque; 42.3% vs. 6.3%, p<0.001) than in 
the patients without recurrence of AF (Table 1). 
Table1. Baseline clinical characteristics and variables associated with recurrence of AF
Baseline clinical characteristics All subjects (n=105) AF recurrence (-) (n=79) AF recurrence (+) (n=26) p
Clinical characteristics
Age (years) 58±11 57±11 062±13 <0.055
Sex (M : F) 76 : 29 57 : 22 19 : 7 <0.927
DM (N, %) 12 (11.4) 5 (6.3) 07 (26.9) <0.009*
Hypertension (N, %) 41 (39)0. 28 (35.4) 13 (50)0. <0.187
Stroke (N, %) 5 (4.8) 4 (5)0. 1 (3.8) <1.000
IHD (N, %) 7 (6.7) 2 (2.6) 05 (20.8) <0.008*
VHD (N, %) 17 (16.2) 13 (18.3) 05 (22.7) <0.758
Smoking (N, %) 9 (8.6) 08 (10.1) 1 (3.8) <0.446
Duration of AF (months) 35.0±66.8 18.1±27.9 032.3±44.3 <0.134
Type (PAF : PeAF) 56 : 49 45 : 34 11 : 15 <0.194
Mitral isthmus line 37 (35.2) 31 (39.2) 6 (23)0 <0.135
Plaque thickness (N, %) <0.001*
<1 mm 56 (53.3) 49 (62.0) 07 (26.9)
1-4 mm 33 (31.4) 25 (31.6) 08 (30.7)
>4 mm 16 (15.2) 5 (6.3) 11 (42.3)
Laboratory findings
FBS (mg/dL) 103.3±18.20 102.3±17.10 106.3±21.0 <0.336
hsCRP (mg/L) 2.13±3.57 2.3±4.0 01.6±1.6 <0.399
BNP (pg/mL) 312.7±508.8 241.8±436.0 0519.7±645.2 <0.059
Cr (mg/dL) 1.02±0.20 1.0±0.2 01.1±0.2 <0.191
TC (mg/dL) 176.4±35.40 178.6±35.90 170.0±33.8 <0.272
TG (mg/dL) 147.0±85.20 156.4±84.80 118.7±81.3 <0.050
HDL-C (mg/dL) 49.2±27.5 46.7±12.9 048.2±16.0 <0.640
LDL-C (mg/dL) 103.8±27.20 105.3±29.10 099.1±20.0 <0.329
Echocardiographic parameters
LVEDD (mm) 49.2±5.50 49.3±5.10 48.9±6.7 <0.741
LVESD (mm) 30.7±5.90 30.4±5.80 31.5±6.6 <0.506
LAD (mm) 41.3±6.90 41.1±6.90 43.3±7.7 <0.221
EF (%) 62.5±6.90 62.5±6.30 62.5±8.6 <0.994
Vmax of LAA (cm/s) 55.3±22.0 57.2±21.8 049.6±22.3 <0.141
Data are expressed as mean±SD or number (%) of patients. *p<0.05. AF: atrial fibrillation, DM: diabetes mellitus, IHD: ischemic heart disease, 
VHD: valvular heart disease, PAF: paroxysmal atrial fibrillation, PeAF: persistent atrial fibrillation, FBS: fasting blood sugar, hsCRP: high sen-
sitive CRP: C-reactive protein, BNP: brain natriuretic peptide, Cr: creatinine, TC: total cholesterol, TG: triglyceride, HDL-C: high density lipo-
protein-cholesterol, LDL-C: low density lipoprotein-cholesterol, LVEDD: left ventricular end diastolic diameter, LVESD: left ventricular end sys-
tolic diameter, LAD: anteroposterior left atrial diameter, EF: left ventricular ejection fraction, Vmax of LAA: peak velocity of left atrial 
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A univariate analysis showed that the presence of diabetes 
{hazard ratio (HR)=3.425; 95% confidence interval (CI), 
1.422-8.249, p=0.006}, IHD (HR=4.549; 95% CI, 1.679-
12.322, p=0.003), duration of AF (HR=1.010; 95% CI, 1.001-
1.018, p=0.025), type of AF (HR=2.412; 95% CI, 1.042-5.584, 
p=0.040) and aortic plaque thickness with >4 mm (HR=9.514; 
95% CI, 3.479-26.015, p<0.001) prior to the ablation proce-
dure were significantly associated with the recurrence of AF 
after ablation (Table 2). In the Cox multivariate regression 
analysis, only the aortic plaque thickness (with >4 mm) was 
an independent predictor of the recurrence of AF after abla-
tion (HR =7.250; 95% CI, 1.906-27.580, p=0.004) (Table 3). 
Discussion
AF is not only the most frequently encountered arrhyth-
mia in clinical practice but it can also cause fatal complica-
tions, such as stroke, thromboembolism and congestive heart 
failure.
1-4) For patients with drug-refractory AF, catheter abla-
tion could be recommended as a therapeutic option, but the 
rate of procedural efficacy was variable according to the re-
port, to represent the success rate of 60-85%.
8)14)15) According 
to the results of several studies, the risk factors for the recur-
rence of AF after ablation could be different based not only 
on the methods of the ablation procedure,
5)8) but also could 
be different from the traditional risk factors even after che-
mical- or electrical-cardioversion.
5-9) This study intended to 
investigate the factors influencing the recurrence of AF after 
3D-guided CPVA and roof line and supplementary mitral is-
thmus isolation procedures.
The relationship between the occurrence of AF and the de-
gree of atherosclerosis has been reported in several studies.
11-13) 
Heeringa et al.
11) demonstrated that intima-media thickness 
(IMT) of the common carotid artery and the presence of caro-
tid plaque are associated with the development of AF. Black-
shear et al.
12) showed that aortic plaque is prevalent in patients 
with AF and is associated with risk factors of atherosclerosis 
such as age, tobacco smoking, DM, hypertension and periph-
eral arterial disease. Agmon et al.
13) demonstrated that AF is 
associated with aortic atherosclerosis and this association is 
related to age since both AF and aortic atherosclerosis are 
more frequent in the elderly population. In this study, we also 
observed that degree of aortic atherosclerosis is associated 
with recurrence of AF after ablation. It has been suggested that 
AF and atherosclerosis share common risk factors such as 
age, hypertension and DM.
12)13) Furthermore, several reports 
demonstrated that oxidative stress and inflammation can play 
an important role in fibrosis and atrial structural remodeling, 
which results in the occurrence of AF.
23-25) Oakes et al.
26) re-
ported that the degree of fibrosis of LA myocardial tissue es-
timated on delayed enhancement magnetic resonance imag-
ing is an independent predictor of recurrence of AF after ab-
lation. Likewise, it has been accepted that fibrosis, including 
oxidative stress and inflammation is also one of well known 
pathophysiologies of atherosclerotic progression.
27)28) In other 
words, recurrence of AF is associated with the degree of fibro-
sis in LA,
26) and atherosclerotic plaque is a product of the in-
flammatory and fibrous response of the aorta.
27)28) Consider-
Table 2. The relationship between recurrence of AF and the vari-
ables
Hazard ratio (95% CI) p
Age (years) 1.039 (0.999-1.081) 0.057
Sex (M : F) 0.975 (0.407-2.335) 0.954
DM 3.425 (1.422-8.249) 0.006*
Hypertension 1.509 (0.687-3.316) 0.306
Stroke 0.652 (0.088-4.830) 0.675
IHD 4.549 (1.679-12.322) 0.003*
VHD 1.405 (0.507-3.895) 0.513
Smoking 0.480 (0.065-3.555) 0.473
Duration of AF (months) 1.010 (1.001-1.018) 0.025*
Type of AF (PeAF : PAF) 2.412 (1.042-5.584) 0.040*
Plaque thickness <0.001*
<1 mm 1 (reference)
1-4 mm 2.419 (0.834-7.017) 0.104
>4 mm 9.514 (3.479-26.015) <0.001*
Echocardiographic parameters
LVEDD (mm) 0.970 (0.888-1.059) 0.493
LVESD (mm) 1.027 (0.947-1.113) 0.522
LAD (mm) 1.037 (0.975-1.104) 0.250
EF (%) 1.000 (0.938-1.065) 0.989
Vmax of LAA (cm/s) 0.987 (0.968-1.006) 0.188
*p<0.05. AF: atrial fibrillation, CI: confidence interval, DM: diabetes 
mellitus, IHD: ischemic heart disease, VHD: valvular heart disease, 
PAF: paroxysmal atrial fibrillation, PeAF: persistent atrial fibrilla-
tion, LVEDD: left ventricular end diastolic diameter, LVESD: left 
ventricular end systolic diameter, LAD: anteroposterior left atrial 
diameter, EF: left ventricular ejection fraction, Vmax of LAA: peak 
velocity of left atrial appendage flow 
Table 3. Multivariate Cox proportional hazards model for recurr-
ence of AF after catheter ablation
Hazard ratio (95% CI) p
DM 1.191 (0.279-5.089) 0.814
IHD 2.509 (0.665-9.464) 0.175
Duration of AF (months) 1.007 (0.996-1.018) 0.240
Type of AF (PAF : PeAF) 1.816 (0.689-4.788) 0.228
Plaque thickness 0.015*
<1 mm 1 (reference)
1-4 mm 2.451 (0.769-7.816) 0.130
>4 mm 7.250 (1.906-27.580) 0.004*
*p<0.05. AF: atrial fibrillation, CI: confidence interval, DM: diabetes 
mellitus, IHD: ischemic heart disease, PAF: paroxysmal atrial fi-
brillation, PeAF: persistent atrial fibrillation182   Aortic Plaque and Atrial Fibrillation 
ing the similarity in the underlying pathophysiology between 
these two processes, the close association between recurrence 
of AF and aortic plaque thickness, therefore, can be surmised. 
Regarding the other risk factors such as the presence of 
diabetes and IHD, duration of AF and type of AF which sh-
owed significant association with the recurrence of AF after 
ablation on univariate analysis: Firstly for diabetes and IHD; 
the number of patients who had DM and/or IHD was may-
be too small to show any significance on multivariate analy-
isis. Secondly for the duration of AF; the duration of AF wh-
ich had been estimated based on the patient’s symptoms and 
ECG documentation was thought to have some inherent 
limitations, and thirdly for the type of AF; there was more re-
currence in the cases with PeAF, but failed to show any sta-
tistically significant difference between the cases with PAF 
and the cases with PeAF.
Berruezo et al.
8) demonstrated that an age of >50 years and 
the presence of PeAF (compared to PAF) were not indepen-
dent predictors of recurrence of AF after CPVA. In addition, 
there was a report showing no significant associations between 
the recurrence of AF and variables, such as age and type of AF 
after ablation.
29) The results of these studies were consistent 
with our results. But, we should consider the fact that the clini-
cal utilization of this procedure was mostly limited to the pa-
tients with AF who were not too elderly.
LA structural and electrical remodeling induces atrial dil-
atation and occurrence of AF respectively.
23-26) Increase in LA 
dimension has been known to be a traditional risk factor for 
recurrence of AF as well as occurrence of AF.
23-26) However, in 
our study we couldn’t find any association between the LA 
size and recurrence of AF. The reason for this discrepancy co-
uldn’t be clarified by the results of this study, but it may be 
related to the limitation that the LA dimension measured by 
TTE correlates poorly with the true LA volume,
29)30) or it may 
be related to the selection bias, since the ablation procedure 
is usually reserved for those patients with no structural heart 
disease, and not for those patients with huge LA. 
The limitations of this study are as follows:
1) We did not perform the other imaging studies, such as 
dynamic aortic CT. Therefore, the aortic plaque located in the 
blind spot of the upper ascending aorta could not be detected. 
Fortunately, plaque lesions are more common in the descend-
ing versus the ascending or aortic arch portion of the thoracic 
arota.
12) 
2) Aortic plaque thickness does not represent the absolute 
degree of atherosclerosis in the aorta. Further studies on the 
atheroma volume should be helpful.
3) This was a retrospective and a single center study in a re-
latively small group of patients. Therefore, large-scale, prospec-
tive, randomized studies are required. 
4) This study showed clinical outcomes of the patients with 
a heterogeneous and a relatively short term follow-up dura-
tion of a period of 23±17 months. The predictors of recurr-
ence of AF in the patients followed up for long term may be 
different than those seen in these results. 
In conclusion, the results of the present study demonstrated 
that a significantly increased aortic plaque thickness may be 
a predictable factor of recurrence of AF after CPVA in pa-
tients with PAF or PeAF. Therefore, an assessment of the aor-
tic plaque thickness can be incorporated into the pre-proce-
dural evaluation in order to make an assumption regarding 
the disease prognosis.
REFERENCES
1) Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation as an indepen-
dent risk factor for stroke: the Framingham Study. Stroke 1991;22: 
983-8.
2) Benjamin EJ, Wolf PA, D’Agostino RB, Silbershatz H, Kannel WB, 
Levy D. Impact of atrial fibrillation on the risk of death: the Framing-
ham Heart Study. Circulation 1998;98:946-52.
3) Wang TJ, Larson MG, Levy D, et al. Temporal relations of atrial fibr-
illation and congestive heart failure and their joint influence on mor-
tality: the Framingham Heart Study. Circulation 2003;107:2920-5.
4) Lee KS, Choi SJ, Park SH, Kim HL, Min H, Park HY. Prevalence of 
atrial fibrillation in middle-aged people in Korea: the Korean genome 
and epidemiology study. Korean Circ J 2008;38:601-5.
5) Sauer WH, McKernan ML, Lin D, Gerstenfeld EP, Callans DJ, Mar-
chlinski FE. Clinical predictors and outcomes associated with acute 
return of pulmonary vein conduction during pulmonary vein isolation 
for treatment of atrial fibrillation. Heart Rhythm 2006;3:1024-8.
6) Feinberg WM, Blackshear JL, Laupacis A, Kronmal R, Hart RG. Pre-
valence, age distribution, and gender of patients with atrial fibrilla-
tion: analysis and implications. Arch Intern Med 1995;155:469-73.
7) Benjamin EJ, Levy D, Vaziri SM, D’Agostino RB, Belanger AJ, 
Wolf PA. Independent risk factors for atrial fibrillation in a popula-
tion-based cohort: the Framingham Heart Study. JAMA 1994;271: 
840-4.
8) Berruezo A, Tamborero D, Mont L, et al. Pre-procedural predictors 
of atrial fibrillation recurrence after circumferential pulmonary vein 
ablation. Eur Heart J 2007;28:836-41.
9) Frost L, Hune LJ, Vestergaard P. Overweight and obesity as risk fac-
tors for atrial fibrillation or flutter: the Danish Diet, Cancer, and He-
alth Study. Am J Med 2005;118:489-95.
10) Goto S, Bhatt DL, Rother J, et al. Prevalence, clinical profile, and car-
diovascular outcomes of atrial fibrillation patients with atherothrom-
bosis. Am Heart J 2008;156:855-63.
11) Heeringa J, van der Kuip DA, Hofman A, et al. Subclinical athero-
sclerosis and risk of atrial fibrillation. Arch Intern Med 2007;167: 
382-7.
12) Blackshear JL, Pearce LA, Hart RG, et al. Aortic plaque in atrial fi-
brillation: prevalence, predictors, and thromboembolic implications. 
Stroke 1999;30:834-40.
13) Agmon Y, Khandheria BK, Meissner I, et al. Association of atrial fi-
brillation and aortic atherosclerosis: a population-based study. Mayo 
Clin Proc 2001;76:252-9.
14) De Potter T, Berruezo A, Mont L, et al. Left ventricular systolic dys-
function by itself does not influence outcome of atrial fibrillation abl-
ation. Europace 2010;12:24-9.
15) Cappato R, Calkins H, Chen SA, et al. Worldwide survey on the me-
thods, efficacy, and safety of catheter ablation for human atrial fibrill-
ation. Circulation 2005;111:1100-5.
16) Chen MS, Marrouche NF, Khaykin Y, et al. Pulmonary vein isolation 
for the treatment of atrial fibrillation in patients with impaired systo-
lic function. J Am Coll Cardiol 2004;43:1004-9.
17) Fuster V, Rydén LE, Cannom DS, et al. ACC/AHA/ESC 2006 guide-Hui-Jeong Hwang, et al.   183
lines for the management of patients with atrial fibrillation. Circula-
tion 2006;114:e257-354.
18) Calvo N, Mont L, Tamborero D, et al. Efficacy of circumferential pul-
monary vein ablation of atrial fibrillation in endurance athletes. Euro-
pace 2010;12:30-6.
19) Natale A, Raviele A, Arentz T, et al. Venice chart international con-
sensus document on atrial fibrillation ablation. J Cardiovasc Electro-
physiol 2007;18:560-80.
20) Stroke Prevention in Atrial Fibrillation Investigators Committee on 
Echocardiography. Transesophageal echocardiography in atrial fibrill-
ation: standards for acquisition and interpretation and assessment of 
interobserver variability. J Am Soc Echocardiogr 1996;9:556-66.
21) Amarenco P, Cohen A, Tzourio C, et al. Atherosclerotic disease of the 
aortic arch and the risk of ischemic stroke. N Engl J Med 1994;331: 
1474-9.
22) Otto CM. Textbook of Clinical Echocardiography. 4th ed. Philadel-
phia: W.B. Saunders Company;2009. p.125-56.
23) Casaclang-Verzosa G, Gersh BJ, Tsang TS. Structural and functional 
remodeling of the left atrium: clinical and therapeutic implications for 
atrial fibrillation. J Am Coll Cardiol 2008;51:1-11.
24) Hwang GS, Kim YH, Kim MK, et al. Gene expression and ultrast-
ructural remodeling in persistent atrial fibrillation. Korean Circ J 
2004;34:693-705. 
25) Park JH, Oh YS, Kim JH, et al. Effect of angiotensin converting en-
zyme inhibitors and angiotensin receptor blockers on patients follow-
ing ablation of atrial fibrillation. Korean Circ J 2009;39:185-9.
26) Oakes RS, Badger TJ, Kholmovski EG, et al. Detection and quantific-
ation of left arterial structural remodeling with delayed-enhancement 
magnetic resonance imaging in patients with atrial fibrillation. Circul-
ation 2009;119:1758-67. 
27) Boisvert WA, Rose DM, Boullier RA, et al. Leukocyte transglutami-
nase 2 expression limits atherosclerotic lesion size. Arterioscler Th-
romb Vasc Biol 2006;26:563-9.
28) Mackey RH, Venkitachalam L, Sutton-Tyrrell K. Calcifications, ar-
terial stiffness and atherosclerosis. Adv Cardiol 2007;44:234-44.
29) Cheema A, Vasamreddy CR, Dalal D, et al. Long-term single proce-
dure efficacy of catheter ablation of atrial fibrillation. J Interv Card Elec-
trophysiol 2006;15:145-55.
30) Hof I, Arbab-Zadeh A, Scherr D, et al. Correlation of left atrial diame-
ter by echocardiography and left atrial volume by computed tomog-
raphy. J Cardiovasc Electrophysiol 2009;20:159-63.